FDA Approves Kisunla, a Novel Alzheimer's Therapy Targeting Amyloid Plaques

FDA Grants Fast-Track Designation to SYNC-T SV-102 for Hard-to-Treat Prostate Cancer

FDA Approves Clinical Trials for ZW171: A Novel Bispecific Antibody for Hard-to-Treat Cancers

FDA Approves Grifols' Yimmugo® for Primary Immunodeficiency, Marking a Milestone

Spinogenix's Daily Pill SPG302 Receives FDA IND Nod for ALS Treatment

New Treatment for AA Hepatitis: Larsucosterol Earns FDA Breakthrough Designation

FDA Approves IMDELLTRA for Lung Cancer After a 40% Response Rate

A New Horizon in Oncology: FDA Approves the First-Ever mRNA Cancer Vaccine

FDA Grants Full Approval for Tivdak® to Treat Recurrent or Metastatic Cervical Cancer

GenFleet Receives FDA Approval for P3 Trial of GFH925 in Colorectal Cancer Treatment

Transformative One-Time Gene Therapy: FDA Approves Pfizer's BEQVEZ, for Hemophilia B

FDA Approves Lutathera as First Treatment for Pediatric Neuroendocrine Tumors

FDA Approves New Imaging System to Enhance Tumor Detection in Cancer Surgery

Roche's Blood Test for Alzheimer's Earns FDA Breakthrough Device Designation

FDA Clears Spinogenix's Phase 2a Trial for Innovative Fragile X Syndrome Treatment

LSTA1 (Certepetide) Wins FDA Orphan Drug Status for Osteosarcoma Treatment

FDA Endorses Sunvozertinib for First-Line Treatment of Lung Cancer with EGFR-E20i

FDA Approves Groundbreaking Gene Therapy for Children with Rare Genetic Disorder

New Hope for Leukemia: FDA Approves Breyanzi, the First CAR T Therapy for CLL and SLL

A New Era in Liver Disease: FDA Approves First Medication 'Rezdiffra' for NASH

FDA Approves Tevimbra for Advanced Esophageal Squamous Cell Carcinoma Treatment

Pancreatic Cancer Therapy Cambritaxestat Receives FDA Orphan Drug Designation

New Hope for Follicular Lymphoma: FDA Grants Accelerated Approval to Brukinsa

FDA Approves Wegovy to Reduce Risk of Heart Problems in Obese Adults

FDA Approves Besponsa for Pediatric Acute Lymphoblastic Leukemia

A New Phase in Bladder Cancer Treatment: Nivolumab Combination Wins FDA Approval

A New Horizon for Lung Cancer: FDA Approves Rybrevant as First-line Therapy

Bayer's New Lung Cancer Drug Receives Critical FDA Breakthrough Designation

FDA Grants Fast Track Designation to NK Cell Therapy AlloNK® for Lupus Nephritis

FDA Approves First Cellular Therapy, Amtagvi, for Treatment of Metastatic Melanoma